MTOR and ovarian cancer: In ovarian cancer, increased ROS production and activation of the AKT/mammalian target of rapamycin (mTOR) signaling pathway were involved in the upregulation of SREBP1 and SREBP2, which promoted cell growth and metastasis [55] (Fig. 1).